{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["5(2)"],"submitter":["Marschner CA"],"funding":["Canadian Heads of Academic Radiology","University Medical Imaging Toronto Academic Incentive Fund","Canadian Association of Radiologists"],"pubmed_abstract":["Purpose
To evaluate potential cardiac sequelae of COVID-19 vaccination at 2-month follow-up and relate cardiac symptoms to myocardial tissue changes on fluorodeoxyglucose (FDG) PET/MRI, blood biomarkers, health-related quality of life, and adverse outcomes.Materials and methods
In this prospective study (ClinicalTrials.gov: NCT04967807), a convenience sample of individuals aged ≥17 years were enrolled after COVID-19 vaccination and were categorized as symptomatic myocarditis (new cardiac symptoms within 14 days of vaccination and met diagnostic criteria for acute myocarditis), symptomatic no myocarditis (new cardiac symptoms but did not meet criteria for myocarditis), and asymptomatic (no new cardiac symptoms). Standardized evaluation was performed 2 months after vaccinatio"],"journal":["Radiology. Cardiothoracic imaging"],"pagination":["e220247"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10037313"],"repository":["biostudies-literature"],"pubmed_title":["Myocardial Inflammation on FDG PET/MRI and Clinical Outcomes in Symptomatic and Asymptomatic Participants after COVID-19 Vaccination."],"pmcid":["PMC10037313"],"pubmed_authors":["Marschner CA","Iwanochko RM","Hanneman K","Cheung AM","Gustafson D","Fish JE","Abdel-Qadir H","Howe KL","Thavendiranathan P","Wald RM","Hong R","Epelman S"],"additional_accession":[]},"is_claimable":false,"name":"Myocardial Inflammation on FDG PET/MRI and Clinical Outcomes in Symptomatic and Asymptomatic Participants after COVID-19 Vaccination.","description":"Purpose
To evaluate potential cardiac sequelae of COVID-19 vaccination at 2-month follow-up and relate cardiac symptoms to myocardial tissue changes on fluorodeoxyglucose (FDG) PET/MRI, blood biomarkers, health-related quality of life, and adverse outcomes.Materials and methods
In this prospective study (ClinicalTrials.gov: NCT04967807), a convenience sample of individuals aged ≥17 years were enrolled after COVID-19 vaccination and were categorized as symptomatic myocarditis (new cardiac symptoms within 14 days of vaccination and met diagnostic criteria for acute myocarditis), symptomatic no myocarditis (new cardiac symptoms but did not meet criteria for myocarditis), and asymptomatic (no new cardiac symptoms). Standardized evaluation was performed 2 months after vaccinatio","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Apr","modification":"2025-04-22T14:04:58.792Z","creation":"2025-02-19T02:04:09.587Z"},"accession":"S-EPMC10037313","cross_references":{"pubmed":["36987440"],"doi":["10.1148/ryct.220247"]}}